These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 34011212)

  • 21. Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn's disease: an observational study.
    Ribaldone DG; Caviglia GP; Pellicano R; Vernero M; Saracco GM; Morino M; Astegiano M
    Rev Esp Enferm Dig; 2020 Mar; 112(3):195-200. PubMed ID: 32054272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: results of a single-centre, retrospective study.
    Chiricozzi A; Zangrilli A; Bavetta M; Bianchi L; Chimenti S; Saraceno R
    J Eur Acad Dermatol Venereol; 2017 Feb; 31(2):304-311. PubMed ID: 27324646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts.
    Derikx LAAP; Dolby HW; Plevris N; Lucaciu L; Rees CS; Lyons M; Siakavellas SI; Constantine-Cooke N; Jenkinson P; Su S; O'Hare C; Kirckpatrick L; Merchant LM; Noble C; Arnott ID; Jones GR; Lees CW
    J Crohns Colitis; 2021 Dec; 15(12):2011-2021. PubMed ID: 34089587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients.
    Mastorino L; Susca S; Cariti C; Sliquini N; Verrone A; Stroppiana E; Ortoncelli M; Dapavo P; Ribero S; Quaglino P
    J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):1848-1853. PubMed ID: 37113043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease - a prospective, multicentre study.
    Lontai L; Gonczi L; Balogh F; Komlodi N; Resal T; Farkas K; Molnar T; Miheller P; Golovics PA; Schafer E; Szamosi T; Ilias A; Lakatos PL
    Dig Liver Dis; 2022 Dec; 54(12):1639-1645. PubMed ID: 35931624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy, immunogenicity and cost analysis of a systematic switch from originator infliximab to biosimilar CT-P13 of all patients with inflammatory arthritis from a single center.
    Valido A; Silva-Dinis J; Saavedra MJ; Iria I; Gonçalves J; Lopes JP; Fonseca JE
    Acta Reumatol Port; 2019; 44(4):303-311. PubMed ID: 31754088
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey.
    Potenza MC; Peris K; Berardesca E; Bianchi L; Richetta A; Bernardini N; De Simone C; Teoli M; Zangrilli A; D'epiro S; Orsini D; Narcisi A; Chimenti S; Costanzo A
    Dermatol Ther; 2018 Jan; 31(1):. PubMed ID: 29215183
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches.
    Blauvelt A; Lacour JP; Fowler JF; Weinberg JM; Gospodinov D; Schuck E; Jauch-Lembach J; Balfour A; Leonardi CL
    Br J Dermatol; 2018 Sep; 179(3):623-631. PubMed ID: 29917226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of switching from adalimumab originator to adalimumab biosimilar in moderate to severe psoriasis patients: A Real-life experience in a tertiary referral centre.
    Gallo G; Rostagno E; Siliquini N; Stroppiana E; Verrone A; Ortoncelli M; Quaglino P; Dapavo P; Ribero S
    Australas J Dermatol; 2021 Aug; 62(3):e431-e432. PubMed ID: 34042171
    [No Abstract]   [Full Text] [Related]  

  • 30. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
    Papoutsaki M; Chimenti MS; Costanzo A; Talamonti M; Zangrilli A; Giunta A; Bianchi L; Chimenti S
    J Am Acad Dermatol; 2007 Aug; 57(2):269-75. PubMed ID: 17574299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator.
    Cingolani L; Barberio B; Zingone F; Ferronato A; Bertani L; Costa F; Bodini G; Demarzo MG; Melatti P; Gubbiotti A; Massimi D; Casadei C; D'Incà R; Savarino EV
    Sci Rep; 2021 May; 11(1):10368. PubMed ID: 33990652
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis.
    Bellinato F; Gisondi P; Mason E; Ricci P; Maurelli M; Girolomoni G
    Dermatol Ther (Heidelb); 2022 Jun; 12(6):1303-1311. PubMed ID: 35476248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical experience with the etanercept biosimilar SB4 in psoriatic patients.
    Pescitelli L; Lazzeri L; Di Cesare A; Tripo L; Ricceri F; Prignano F
    Int J Clin Pharm; 2019 Feb; 41(1):9-12. PubMed ID: 30610544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ABP 501 for the treatment of rheumatoid arthritis.
    Pelechas E; Voulgari PV; Drosos AA
    Expert Opin Biol Ther; 2018 Mar; 18(3):317-322. PubMed ID: 29350566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SB5: An Adalimumab Biosimilar.
    Frampton JE
    BioDrugs; 2018 Oct; 32(5):507-510. PubMed ID: 30251234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study.
    Talamonti M; Galluzzo M; Bernardini N; Caldarola G; Persechino S; Cantoresi F; Egan CG; Potenza C; Peris K; Bianchi L
    J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1737-1744. PubMed ID: 29776016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biosimilars for the Treatment of Psoriasis: A Systematic Review of Clinical Trials and Observational Studies.
    Phan DB; Elyoussfi S; Stevenson M; Lunt M; Warren RB; Yiu ZZN
    JAMA Dermatol; 2023 Jul; 159(7):763-771. PubMed ID: 37256582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial.
    Goll GL; Jørgensen KK; Sexton J; Olsen IC; Bolstad N; Haavardsholm EA; Lundin KEA; Tveit KS; Lorentzen M; Berset IP; Fevang BTS; Kalstad S; Ryggen K; Warren DJ; Klaasen RA; Asak Ø; Baigh S; Blomgren IM; Brenna Ø; Bruun TJ; Dvergsnes K; Frigstad SO; Hansen IM; Hatten ISH; Huppertz-Hauss G; Henriksen M; Hoie SS; Krogh J; Midtgard IP; Mielnik P; Moum B; Noraberg G; Poyan A; Prestegård U; Rashid HU; Strand EK; Skjetne K; Seeberg KA; Torp R; Ystrøm CM; Vold C; Zettel CC; Waksvik K; Gulbrandsen B; Hagfors J; Mørk C; Jahnsen J; Kvien TK
    J Intern Med; 2019 Jun; 285(6):653-669. PubMed ID: 30762274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost-effectiveness?
    Roccuzzo G; Rozzo G; Burzi L; Repetto F; Dapavo P; Ribero S; Quaglino P
    Dermatol Ther; 2022 Nov; 35(11):e15803. PubMed ID: 36062429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Switching patterns of biological drugs in patients with psoriasis and psoriatic arthritis: insight from the VALORE database network.
    Spini A; Pellegrini G; Ingrasciotta Y; L'Abbate L; Bellitto C; Carollo M; Leoni O; Zanforlini M; Ancona D; Stella P; Cavazzana A; Scapin A; Lopes S; Belleudi V; Ledda S; Carta P; Rossi P; Ejlli L; Sapigni E; Puccini A; Spila Alegiani S; Massari M; Guarneri C; Gisondi P; Trifirò G
    Expert Opin Biol Ther; 2024 May; 24(5):399-409. PubMed ID: 38767132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.